A Phase 2 Multi-Centre Study to Characterise the Pharmacodynamics of Vessel Dilator Peptide (VSDL) in Patients with Acute Decompensated Congestive Heart Failure to be assessed by effects on renal function.
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2018
Price : $35 *
At a glance
- Drugs Atrial-natriuretic-factor-prohormone-31-67 (Primary) ; Atrial-natriuretic-factor-prohormone-31-67 (Primary)
- Indications Decompensated heart failure
- Focus Pharmacodynamics
- Acronyms CONTINUUM-HF
- 30 Jul 2018 Status changed from recruiting to discontinued.
- 04 Aug 2014 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry record.
- 01 Oct 2013 New trial record